Trials / Completed
CompletedNCT02546388
Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Marcelo F. Di Carli, MD, FACC · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study to find out if a drug called OctreoScan or DOTATATE can help doctors diagnose people with cardiac sarcoidosis better. OctreoScan and DOTATATE are both approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Indium-111 Pentreotide | |
| DRUG | Gallium-68 DOTATATE |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2018-08-01
- Completion
- 2018-08-01
- First posted
- 2015-09-10
- Last updated
- 2020-04-09
- Results posted
- 2020-03-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02546388. Inclusion in this directory is not an endorsement.